DCF — GENESYS REGIONAL MEDICAL CTR.
Enterprise Value: $-583.5M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-583.5M
Enterprise Value
$-184.9M
PV of Cash Flows
$-398.6M
PV of Terminal Value
$-641.9M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $374.3M | $-36.2M | -10.0% | $-52.0M | $-47.3M |
| Year 2 | $385.6M | $-33.4M | -9.0% | $-49.7M | $-41.1M |
| Year 3 | $397.1M | $-30.4M | -8.0% | $-47.3M | $-35.5M |
| Year 4 | $409.0M | $-29.3M | -7.0% | $-46.6M | $-31.8M |
| Year 5 | $421.3M | $-29.1M | -7.0% | $-47.0M | $-29.2M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-583.5M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$363.4M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.10165986474448505
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5